Furthermore, a recent case report showed a radical tumor reduction in the papillary craniopharyngioma following a combination therapy with BRAF (dabrafenib) and MEK inhibitors (trametinib) [1]. Here, MAP2K7 is linked to Papillary Craniopharyngioma.